Long-Term Increase in mVEGF ₁₆₄ in Mouse Hindlimb Muscle Mediated by Phage ø C31 Integrase After Nonviral DNA Delivery

Citations Over TimeTop 13% of 2006 papers

Abstract

Peripheral vascular disease (PVD), characterized by insufficient blood supply to extremities, can be a devastating illness. Although many gene therapy strategies for PVD using vascular endothelial growth factor (VEGF) have resulted in increased blood vessel formation, the vessels are often impermanent and regress after therapy, probably because of the short-lived VEGF expression mediated by gene therapy vectors (14 days or less). phiC31 integrase is a recombinase originally isolated from a bacteriophage of Streptomyces. This integrase performs efficient chromosomal integration of plasmid DNA into mammalian genomes that results in long-term transgene expression. In this study, gene transfer was achieved by intramuscular injection of VEGF and integrase plasmid DNAs into the tibialis anterior muscle in the mouse hindlimb, followed by electroporation of the muscle with needle electrodes. We observed VEGF levels significantly above background 40 days after injection in animals that received phiC31 integrase and the VEGF plasmid. Site-specific integration of plasmid DNA in the chromosomes of muscle tissue was verified by polymerase chain reaction at a common integration site. These results suggest the possible utility of the phiC31 integrase system to treat ischemic disease.

Related Papers

• → Optimizing Electroporation Conditions for the Transformation of Mammalian Cells(2003)34 cited
• → Using the Gene Pulser MXcell Electroporation System to Transfect Primary Cells with High Efficiency(2010)11 cited
• → Optimal parameters of electroporation for gene and tissue(2012)5 cited
• → Using the Gene Pulser MXcell Electroporation System to Transfect Primary Cells with High Efficiency(2010)1 cited
• Inhibitory effect of Ca^2＋ on in vivo gene transfer by electroporation(2006)